Stay updated on Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page
- CheckyesterdayChange DetectedRevision: v3.3.4 appears and v3.3.3 is removed. This is a minor metadata update that does not change the study details.SummaryDifference0.0%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe study record now includes a Locations section with multiple site locations (Arizona, California, Colorado, Florida, Maryland, Massachusetts, Missouri, New York, Pennsylvania, Tennessee, Texas, Washington, Alberta, Ontario, Chiba, Tokyo, Lanarkshire). The previous location listings were removed, and the revision is v3.3.3.SummaryDifference1%

- Check52 days agoChange DetectedRevision: v3.3.2 has been added and Revision: v3.2.0 has been removed. This update pertains to versioning and does not modify any study data, eligibility criteria, or listed locations.SummaryDifference0.0%

- Check59 days agoChange DetectedA government funding status notice banner was removed from the page, eliminating the warning about updates and operating status. The study details and main content remain unchanged.SummaryDifference0.2%

- Check73 days agoChange DetectedResults for the study are now posted, including primary/secondary outcomes and updated completion dates.SummaryDifference0.3%

- Check102 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference2%

Stay in the know with updates to Cabiralizumab Combo in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabiralizumab Combo in Pancreatic Cancer Clinical Trial page.